A biomimetic strategy is developed to enhance inflamed BBB‐targeting gene delivery using cationic hybrid nanovesicles derived from mesenchymal stem cell membranes, named P(ML), offering potential therapeutic applications for ischemic stroke and other BBB‐related disorders.
Abstract
Blood–brain barrier (BBB) disruption is found in many acute and chronic inflammatory encephalopathies. Timely restoration of BBB integrity is essential for controlling disease progression, especially in ischemic stroke. While various brain‐targeting strategies have been developed, achieving precise BBB‐targeting and sustained retention at the BBB to enable faster and more effective repair remains a significant challenge. In this study, a biomimetic strategy is developed to enhance inflamed BBB‐targeting gene delivery using cationic hybrid nanovesicles derived from mesenchymal stem cell (MSC) membranes, named P(ML). The combined contributions of the positive surface charge and the biological targeting capability inherent to MSC membranes enable the precise inflamed BBB‐targeting of P(ML). In vitro and in vivo studies demonstrated that P(ML) efficiently accumulated in ischemic brain regions, and exhibited precise retention at inflamed BBB, rather than a diffuse distribution within the whole brain. Additionally, P(ML) showed efficient nucleic acid delivery capability. When loaded with siRNA targeting p66Shc, a protein involved in endothelial dysfunction, P(ML) exhibited significant protective effects on the injured BBB in animal models. This biomimetic P(ML) nanocarrier platform represents a promising strategy for inflamed BBB‐targeting gene delivery, offering potential therapeutic applications for ischemic stroke and other BBB‐related disorders.
The concept of achieving sustained high brain exposure by combining BBB transport with enhanced brain retention with binding to blood–brain barrier (BBB) proteins for enhanced BBB permeability was shown to be broadly applicable.
Yukihiro Noguchi, Naoka Hironiwa, Kazuki Sato et al.· mAbs· 0 citations
This study presents a ligand-free lipid nanoparticle (LNP) platform that enables efficient mRNA delivery to the brain endothelium via systemic administration and establishes a new class of cholesterol-based lipids that provides a foundation for next-generation RNA therapeutics targeting BBB-associated diseases.
Ze-Ru Tian, Xu Wang, A. Benitez et al.· Advances in Materials· 0 citations
Multimodal strategies integrating RMT, stimuli-responsive carriers, and CRISPRbased gene delivery may collectively overcome the translational gap that single-platform approaches have consistently failed to bridge.
Manish R. Bhise, K. Thejomoorthy, Mohit Kumar et al.· Current Drug Delivery· 0 citations
Personalized delivery designs guided by cascade targeting, dynamic visualization-based validation and disease stratification are proposed to support precise treatment of CNS inflammation and brain tumors.
Man-Ru Zhang, Bo-Han Chen, Tie-Zheng Li et al.· Pharmaceutics· 0 citations
Effective treatment of brain diseases is limited by poor blood-brain barrier (BBB) penetration of drugs and their nanosized carriers. The intracellular transport of nanocarriers in brain microvessel endothelial cells (BMECs) significantly affects BBB-crossing efficiency. Most nanocarriers follow the lysosomal degra...
Li Zhang, He-Mei Cheng, Nian Wang et al.· Nano Reseach· 0 citations
Ischemic stroke (IS) is one of the primary causes of global mortality and permanent neurological disability, and its clinical treatment is severely constrained by the intricate ischemic pathological cascade and the impermeable blood‐brain barrier (BBB). Cerebral ischemia and reperfusion trigger a series of pathologic...
Yan-Han Huang, Xuan Hou, Haiping Zhao et al.· Responsive Materials· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.